What is Antibe Therapeutics Inc. (ATE.TO)?

Antibe Therapeutics Inc. (ATE.TO) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

Antibe Therapeutics Inc. (ATE.TO)

Stock analysis · TSX · Healthcare · Medical - Devices

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.19

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Antibe Therapeutics Inc. (ATE.TO) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Feb 19, 2024

EPS $-0.08 vs est. $-0.11

Beat by $0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.